Sun sets out $11.75bn takeover play for Organon
After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
Newsletters and Deep Dive digital magazine
After downplaying persistent rumours for months, Sun Pharma has broken cover with an $11.75 billion takeover agreement for Organon.
March saw a handful of noteworthy hires in the agency, consultancy, and investor spaces.
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
Roche has started its financial reporting for 2026 with a 5% fall in first-quarter revenues, but says its underlying performance remains strong.
Editor's Picks
Newsletters and Deep Dive
digital magazine